Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Serum urate (uric acid) (sUA) level < 6 mg/dL from the end of month 9 to the end of month 12

Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL for the 3-month period from the end of month 9 to the end of month 12

Time frame: 12 weeks

No gout flares from the end of month 9 to the end of month 12

Comparison of the treatment groups for the proportion of patients with no gout flares for the 3-month period from the end of month 9 to the end of month 12

Time frame: 12 weeks

Change in tophus burden by month 12

Comparison of the treatment groups for the proportion of patients who experience a complete response, marked or partial response, of at least 1 target tophus at Month 12, with no evidence of disease progression (no new tophus or single tophus showing progression) and patients with no new tophi formation at month 12 as determined using the computer-assisted photographic evaluation in rheumatology (CAPER) method

Time frame: 48 weeks

Incidence of Adverse Events

Treatment Emergent Adverse Events and Serious Adverse Event incidence

Time frame: 56 weeks